Company news
Regenxbio Inc. news in 2020
Regenxbio Inc.'s news releases, calls and decks from 2020, newest first.
REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million
December 21, 2020
REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
December 9, 2020
REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II
December 7, 2020
REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
November 30, 2020
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting
November 9, 2020
REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights
November 3, 2020
REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights
October 27, 2020
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
October 26, 2020
REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)
September 29, 2020
REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
September 8, 2020
REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
August 24, 2020
REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights
August 5, 2020
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
August 3, 2020
REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
July 29, 2020
REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases
July 7, 2020
REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights
May 6, 2020
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting
April 27, 2020
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
April 21, 2020
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
March 30, 2020
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
February 25, 2020
REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
February 18, 2020
REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium™ 2020
January 28, 2020